NO991926D0 - Oppl°selige lymfotoksin-<beta> reseptorer, anti-lymfotoksinreseptor antistoff samt anti-lymfotoksin-ligand antistoff som terapeutiske midler til behandling av immunologiske sykdommer - Google Patents

Oppl°selige lymfotoksin-<beta> reseptorer, anti-lymfotoksinreseptor antistoff samt anti-lymfotoksin-ligand antistoff som terapeutiske midler til behandling av immunologiske sykdommer

Info

Publication number
NO991926D0
NO991926D0 NO991926A NO991926A NO991926D0 NO 991926 D0 NO991926 D0 NO 991926D0 NO 991926 A NO991926 A NO 991926A NO 991926 A NO991926 A NO 991926A NO 991926 D0 NO991926 D0 NO 991926D0
Authority
NO
Norway
Prior art keywords
lymphotoxin
antibody
beta
receptors
treatment
Prior art date
Application number
NO991926A
Other languages
English (en)
Other versions
NO991926L (no
NO328540B1 (no
Inventor
Jeffrey Browning
Paula Susan Hochman
Paul D Rennert
Fabienne Mackay
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO991926D0 publication Critical patent/NO991926D0/no
Publication of NO991926L publication Critical patent/NO991926L/no
Publication of NO328540B1 publication Critical patent/NO328540B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19991926A 1996-10-25 1999-04-22 Anvendelse av et lymfotoksin-beta-reseptorblokkerende middel for fremstilling av medikamenter mot autoimmune lidelser NO328540B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2906096P 1996-10-25 1996-10-25
PCT/US1997/019436 WO1998017313A2 (en) 1996-10-25 1997-10-24 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Publications (3)

Publication Number Publication Date
NO991926D0 true NO991926D0 (no) 1999-04-22
NO991926L NO991926L (no) 1999-06-25
NO328540B1 NO328540B1 (no) 2010-03-15

Family

ID=21847003

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991926A NO328540B1 (no) 1996-10-25 1999-04-22 Anvendelse av et lymfotoksin-beta-reseptorblokkerende middel for fremstilling av medikamenter mot autoimmune lidelser

Country Status (25)

Country Link
EP (1) EP0954333B1 (no)
JP (1) JP4299887B2 (no)
KR (1) KR100584704B1 (no)
CN (2) CN100382844C (no)
AT (1) ATE331531T1 (no)
AU (1) AU726357B2 (no)
BG (1) BG63565B1 (no)
BR (1) BR9712670A (no)
CA (1) CA2269614A1 (no)
CZ (1) CZ142899A3 (no)
DE (1) DE69736244T2 (no)
DK (1) DK0954333T3 (no)
EA (1) EA002983B1 (no)
EE (1) EE05213B1 (no)
ES (1) ES2268727T3 (no)
HU (1) HU226467B1 (no)
IL (1) IL129527A (no)
IS (1) IS5031A (no)
NO (1) NO328540B1 (no)
NZ (1) NZ335353A (no)
PL (1) PL190617B1 (no)
PT (1) PT954333E (no)
SK (1) SK55399A3 (no)
TR (1) TR199901636T2 (no)
WO (1) WO1998017313A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
CZ20011272A3 (cs) * 1998-10-09 2001-09-12 Biogen, Inc. Použití činidla, které blokuje vazbu lymfotoxinu-beta na jeho receptor, pro výrobu protivirového léku
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
PL353057A1 (en) * 1999-06-28 2003-10-06 Basf Aktiengesellschaft Method for preventing tumoral growth
DE19939653A1 (de) * 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DE60143231D1 (de) * 2000-04-12 2010-11-18 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden Proteins von Herpes Simplex und Methoden zu dessen Verwendungen
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
UA94484C2 (uk) 2006-10-12 2011-05-10 Дженентек, Інк. Антитіла до лімфотоксину-альфа
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN101600450A (zh) 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
WO2010136480A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102360196B1 (ko) 2019-10-30 2022-02-08 주식회사 친환경테크 다용도 시트 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150249A1 (en) * 1992-12-04 1994-06-23 Jeffrey Browning Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Also Published As

Publication number Publication date
CA2269614A1 (en) 1998-04-30
PL190617B1 (pl) 2005-12-30
SK55399A3 (en) 2000-10-09
BG63565B1 (bg) 2002-05-31
NZ335353A (en) 2000-09-29
EA002983B1 (ru) 2002-12-26
CN100382844C (zh) 2008-04-23
CZ142899A3 (cs) 1999-07-14
IL129527A (en) 2006-12-10
AU726357B2 (en) 2000-11-02
KR100584704B1 (ko) 2006-05-30
DK0954333T3 (da) 2006-10-23
ES2268727T3 (es) 2007-03-16
PL332972A1 (en) 1999-10-25
WO1998017313A2 (en) 1998-04-30
EA199900409A1 (ru) 2000-02-28
DE69736244D1 (de) 2006-08-10
EP0954333B1 (en) 2006-06-28
DE69736244T2 (de) 2007-05-31
WO1998017313A3 (en) 1998-07-30
AU5089698A (en) 1998-05-15
KR20000052800A (ko) 2000-08-25
JP4299887B2 (ja) 2009-07-22
CN1237910A (zh) 1999-12-08
ATE331531T1 (de) 2006-07-15
BR9712670A (pt) 1999-10-19
HUP9904516A2 (hu) 2000-05-28
HUP9904516A3 (en) 2002-09-30
IS5031A (is) 1999-04-21
EE9900146A (et) 1999-12-15
TR199901636T2 (xx) 1999-09-21
JP2001502697A (ja) 2001-02-27
HK1025500A1 (en) 2000-11-17
NO991926L (no) 1999-06-25
NO328540B1 (no) 2010-03-15
HU226467B1 (en) 2008-12-29
EP0954333A2 (en) 1999-11-10
IL129527A0 (en) 2000-02-29
PT954333E (pt) 2006-10-31
EE05213B1 (et) 2009-10-15
CN101239186A (zh) 2008-08-13
BG103416A (en) 2000-01-31

Similar Documents

Publication Publication Date Title
NO991926L (no) Oppl°selige lymfotoksin-&lt;beta&gt; reseptorer, anti-lymfotoksin-reseptor antistoff samt anti-lymfotoksin-ligand antistoff som terapeutiske midler til behandling av immunologiske sykdommer
FI980122A0 (fi) Loesliga lymfotoxin- -receptorer och anti-lymfotoxinreceptor och ligandantikroppar som terapeutiska medel foer behandling av immunologisk sjukdom
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
PT817847E (pt) Receptor de il-17
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
DE69839992D1 (de) Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
DK0639275T3 (da) Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
TR199700956T1 (xx) Indazolkarboksamidler.
DE69920717D1 (de) Glucocorticoid selektive entzündungshemmende mittel
EP1723967A3 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees